JPWO2020014366A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020014366A5 JPWO2020014366A5 JP2021500519A JP2021500519A JPWO2020014366A5 JP WO2020014366 A5 JPWO2020014366 A5 JP WO2020014366A5 JP 2021500519 A JP2021500519 A JP 2021500519A JP 2021500519 A JP2021500519 A JP 2021500519A JP WO2020014366 A5 JPWO2020014366 A5 JP WO2020014366A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- polypeptide
- isolated nucleic
- seq
- identity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920001184 polypeptide Polymers 0.000 claims description 56
- 210000004027 cells Anatomy 0.000 claims description 51
- 150000007523 nucleic acids Chemical class 0.000 claims description 47
- 108020004707 nucleic acids Proteins 0.000 claims description 46
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 30
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 28
- 230000011664 signaling Effects 0.000 claims description 20
- 239000000427 antigen Substances 0.000 claims description 17
- 102000038129 antigens Human genes 0.000 claims description 17
- 108091007172 antigens Proteins 0.000 claims description 17
- 230000027455 binding Effects 0.000 claims description 17
- 102100010782 EGFR Human genes 0.000 claims description 11
- 101700039191 EGFR Proteins 0.000 claims description 11
- 108020001756 ligand binding domains Proteins 0.000 claims description 10
- 108020004017 nuclear receptors Proteins 0.000 claims description 10
- 102000006255 nuclear receptors Human genes 0.000 claims description 10
- 102100019461 CD28 Human genes 0.000 claims description 7
- 101700033362 CD28 Proteins 0.000 claims description 7
- 206010000880 Acute myeloid leukaemia Diseases 0.000 claims description 6
- 206010008958 Chronic lymphocytic leukaemia Diseases 0.000 claims description 6
- 208000000429 Leukemia, Lymphocytic, Chronic, B-Cell Diseases 0.000 claims description 6
- 208000007046 Leukemia, Myeloid, Acute Diseases 0.000 claims description 6
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 6
- 201000005510 acute lymphocytic leukemia Diseases 0.000 claims description 6
- 230000004568 DNA-binding Effects 0.000 claims description 4
- 210000002356 Skeleton Anatomy 0.000 claims description 4
- 210000000400 T-Lymphocytes, Cytotoxic Anatomy 0.000 claims description 4
- 241001648840 Thosea asigna virus Species 0.000 claims description 4
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims description 4
- 239000012528 membrane Substances 0.000 claims description 4
- 206010005003 Bladder cancer Diseases 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
- 206010025650 Malignant melanoma Diseases 0.000 claims description 3
- 206010028980 Neoplasm Diseases 0.000 claims description 3
- 206010033128 Ovarian cancer Diseases 0.000 claims description 3
- 240000007019 Oxalis corniculata Species 0.000 claims description 3
- 208000008443 Pancreatic Carcinoma Diseases 0.000 claims description 3
- 206010060862 Prostate cancer Diseases 0.000 claims description 3
- 206010057644 Testis cancer Diseases 0.000 claims description 3
- 206010046766 Uterine cancer Diseases 0.000 claims description 3
- 201000005188 adrenal gland cancer Diseases 0.000 claims description 3
- 229920003013 deoxyribonucleic acid Polymers 0.000 claims description 3
- 201000005202 lung cancer Diseases 0.000 claims description 3
- 201000001441 melanoma Diseases 0.000 claims description 3
- 201000002528 pancreatic cancer Diseases 0.000 claims description 3
- 201000003120 testicular cancer Diseases 0.000 claims description 3
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 3
- 230000003612 virological Effects 0.000 claims description 3
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 206010025310 Other lymphomas Diseases 0.000 claims description 2
- 230000001684 chronic Effects 0.000 claims description 2
- 230000002147 killing Effects 0.000 claims description 2
- 230000021633 leukocyte mediated immunity Effects 0.000 claims description 2
- 210000003289 regulatory T cell Anatomy 0.000 claims description 2
- 230000001177 retroviral Effects 0.000 claims description 2
- 230000004936 stimulating Effects 0.000 claims description 2
- 210000001519 tissues Anatomy 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 4
- 101700041974 NR1H2 Proteins 0.000 claims 3
- 206010024324 Leukaemias Diseases 0.000 claims 2
- 230000004913 activation Effects 0.000 claims 2
- 108020001507 fusion proteins Proteins 0.000 claims 2
- 102000037240 fusion proteins Human genes 0.000 claims 2
- 230000004068 intracellular signaling Effects 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 230000002018 overexpression Effects 0.000 claims 2
- 230000000638 stimulation Effects 0.000 claims 2
- 210000001185 Bone Marrow Anatomy 0.000 claims 1
- 230000001413 cellular Effects 0.000 claims 1
- 210000002768 hair cell Anatomy 0.000 claims 1
- 230000003834 intracellular Effects 0.000 claims 1
- 230000031146 intracellular signal transduction Effects 0.000 claims 1
- 238000002955 isolation Methods 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 230000026683 transduction Effects 0.000 claims 1
- 238000010361 transduction Methods 0.000 claims 1
- 210000001744 T-Lymphocytes Anatomy 0.000 description 4
- 201000009277 hairy cell leukemia Diseases 0.000 description 4
- 208000008456 Leukemia, Myelogenous, Chronic, BCR-ABL Positive Diseases 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 201000006934 chronic myeloid leukemia Diseases 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 229920001850 Nucleic acid sequence Polymers 0.000 description 2
- 229920000023 polynucleotide Polymers 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 206010028549 Myeloid leukaemia Diseases 0.000 description 1
- 206010029592 Non-Hodgkin's lymphomas Diseases 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024022330A JP2024073449A (ja) | 2018-07-10 | 2024-02-16 | Ｒｏｒ－１特異的キメラ抗原受容体およびその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862696075P | 2018-07-10 | 2018-07-10 | |
| US62/696,075 | 2018-07-10 | ||
| PCT/US2019/041213 WO2020014366A1 (fr) | 2018-07-10 | 2019-07-10 | Récepteurs antigéniques chimériques specifiques de ror-1 et utilisations associées |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024022330A Division JP2024073449A (ja) | 2018-07-10 | 2024-02-16 | Ｒｏｒ－１特異的キメラ抗原受容体およびその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021530217A JP2021530217A (ja) | 2021-11-11 |
| JPWO2020014366A5 true JPWO2020014366A5 (fr) | 2022-07-12 |
Family
ID=69141807
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021500519A Pending JP2021530217A (ja) | 2018-07-10 | 2019-07-10 | Ｒｏｒ−１特異的キメラ抗原受容体およびその使用 |
| JP2024022330A Pending JP2024073449A (ja) | 2018-07-10 | 2024-02-16 | Ｒｏｒ－１特異的キメラ抗原受容体およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024022330A Pending JP2024073449A (ja) | 2018-07-10 | 2024-02-16 | Ｒｏｒ－１特異的キメラ抗原受容体およびその使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20210177902A1 (fr) |
| EP (1) | EP3820484A4 (fr) |
| JP (2) | JP2021530217A (fr) |
| KR (1) | KR20210043562A (fr) |
| CN (1) | CN112714769A (fr) |
| AU (1) | AU2019301147A1 (fr) |
| CA (1) | CA3105816A1 (fr) |
| IL (1) | IL280029A (fr) |
| SG (1) | SG11202100205UA (fr) |
| WO (1) | WO2020014366A1 (fr) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11629340B2 (en) | 2017-03-03 | 2023-04-18 | Obsidian Therapeutics, Inc. | DHFR tunable protein regulation |
| CA3079264A1 (fr) * | 2017-10-18 | 2019-04-25 | Intrexon Corporation | Compositions polypeptidiques comprenant des espaceurs |
| JPWO2020085480A1 (ja) * | 2018-10-26 | 2021-09-16 | 国立大学法人信州大学 | 高効率な遺伝子改変細胞の作製方法 |
| US20220332780A1 (en) | 2019-09-10 | 2022-10-20 | Obsidian Therapeutics, Inc. | Ca2-il15 fusion proteins for tunable regulation |
| JP2023518293A (ja) | 2020-03-20 | 2023-04-28 | ライル・イミュノファーマ，インコーポレイテッド | 新規の組換え細胞表面マーカー |
| WO2021191870A1 (fr) | 2020-03-27 | 2021-09-30 | Dcprime B.V. | Utilisation ex vivo de cellules modifiées d'origine leucémique pour améliorer l'efficacité d'une thérapie cellulaire adoptive |
| AU2021375493A1 (en) | 2020-11-05 | 2023-06-29 | Mendus B.V. | Use of tumor-independent antigens in immunotherapies |
| TW202233662A (zh) * | 2020-12-31 | 2022-09-01 | 大陸商亘喜生物科技（上海）有限公司 | 膜融合蛋白及其在免疫細胞中的應用 |
| MX2023008115A (es) * | 2021-01-11 | 2023-09-11 | Precigen Inc | Terapia con receptores quiméricos. |
| WO2022188652A1 (fr) * | 2021-03-09 | 2022-09-15 | 四川科伦博泰生物医药股份有限公司 | Protéine de liaison à ror1 et son utilisation |
| KR20240109617A (ko) | 2021-10-28 | 2024-07-11 | 라이엘 이뮤노파마, 인크. | Ror1-결합 단백질을 발현하는 세포를 배양하는 방법 |
| WO2024064958A1 (fr) | 2022-09-23 | 2024-03-28 | Lyell Immunopharma, Inc. | Procédés de culture de cellules déficientes en nr4a |
| WO2024064952A1 (fr) | 2022-09-23 | 2024-03-28 | Lyell Immunopharma, Inc. | Procédés de culture de cellules déficientes en nr4a surexprimant c-jun |
| WO2024077174A1 (fr) | 2022-10-05 | 2024-04-11 | Lyell Immunopharma, Inc. | Procédés de culture de cellules déficientes en nr4a |
| CN118206620A (zh) * | 2022-12-09 | 2024-06-18 | 上海细胞治疗集团股份有限公司 | 一种多肽标签及其应用 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9242014B2 (en) * | 2010-06-15 | 2016-01-26 | The Regents Of The University Of California | Receptor tyrosine kinase-like orphan receptor 1 (ROR1) single chain Fv antibody fragment conjugates and methods of use thereof |
| CN103534355A (zh) * | 2011-03-04 | 2014-01-22 | 英特瑞克斯顿股份有限公司 | 条件性表达蛋白质的载体 |
| EA033110B1 (ru) * | 2012-04-11 | 2019-08-30 | Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез | Химерный рецептор антигена, направленный на антиген созревания b-клеток, кодирующая его нуклеиновая кислота, соответствующие экспрессионный вектор, клетка-хозяин, применения и способы |
| CN104854133B (zh) * | 2012-10-12 | 2018-10-30 | 新加坡科技研究局 | 用于制备重组抗体治疗剂的最佳重链和轻链信号肽 |
| US9657105B2 (en) * | 2013-03-15 | 2017-05-23 | City Of Hope | CD123-specific chimeric antigen receptor redirected T cells and methods of their use |
| ES2876925T3 (es) * | 2014-07-29 | 2021-11-15 | Cellectis | Receptores de antígeno quiméricos específicos para ROR1 (NTRKR1) para inmunoterapia contra el cáncer |
| WO2016016343A1 (fr) * | 2014-07-31 | 2016-02-04 | Cellectis | Recepteur d'antigene chimere a chaines multiples specifique de ror1 |
| AU2016206457B2 (en) * | 2015-01-16 | 2021-11-11 | Juno Therapeutics, Inc. | Antibodies and chimeric antigen receptors specific for ROR1 |
| JP2018521004A (ja) * | 2015-05-18 | 2018-08-02 | ユーリカ セラピューティックス， インコーポレイテッド | 抗ｒｏｒ１キメラ抗原受容体 |
| AU2017244108B2 (en) * | 2016-03-29 | 2021-03-18 | University Of Southern California | Chimeric antigen receptors targeting cancer |
| KR102652827B1 (ko) * | 2016-06-08 | 2024-04-01 | 프레시전 인코포레이티드 | Cd33 특이적 키메라 항원 수용체 |
| CN110234327A (zh) * | 2016-11-30 | 2019-09-13 | 英特拉克森公司 | 类固醇施用和免疫疗法 |
| US11408005B2 (en) * | 2016-12-12 | 2022-08-09 | Seattle Children's Hospital | Chimeric transcription factor variants with augmented sensitivity to drug ligand induction of transgene expression in mammalian cells |
| AU2018207281B2 (en) * | 2017-01-10 | 2024-08-01 | Precigen, Inc. | Modulating expression of polypeptides via new gene switch expression systems |
| CA3079264A1 (fr) * | 2017-10-18 | 2019-04-25 | Intrexon Corporation | Compositions polypeptidiques comprenant des espaceurs |
-
2019
- 2019-07-10 CN CN201980059126.7A patent/CN112714769A/zh active Pending
- 2019-07-10 KR KR1020217002650A patent/KR20210043562A/ko unknown
- 2019-07-10 JP JP2021500519A patent/JP2021530217A/ja active Pending
- 2019-07-10 CA CA3105816A patent/CA3105816A1/fr active Pending
- 2019-07-10 WO PCT/US2019/041213 patent/WO2020014366A1/fr unknown
- 2019-07-10 AU AU2019301147A patent/AU2019301147A1/en active Pending
- 2019-07-10 EP EP19833113.4A patent/EP3820484A4/fr active Pending
- 2019-07-10 SG SG11202100205UA patent/SG11202100205UA/en unknown
-
2021
- 2021-01-07 US US17/143,386 patent/US20210177902A1/en active Pending
- 2021-01-07 IL IL280029A patent/IL280029A/en unknown
-
2024
- 2024-02-16 JP JP2024022330A patent/JP2024073449A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20220002401A1 (en) | Chimeric antigen receptor and its use | |
| ES2905557T3 (es) | Receptor de antígeno quimérico anti-CD30 y su uso | |
| JP2019517267A5 (fr) | ||
| CN109415409B (zh) | Flag标记的cd19-car-t细胞 | |
| JPWO2020014366A5 (fr) | ||
| JP2023082052A (ja) | キメラ抗原受容体およびその使用 | |
| CN107922951B (zh) | 抗磷脂酰肌醇蛋白聚糖-1-免疫抗原受体 | |
| CN110872577A (zh) | 修饰的免疫细胞及其应用 | |
| TWI753141B (zh) | 嵌合抗原受體 | |
| TWI811278B (zh) | 表現特異性辨識人類間皮素之細胞表面分子、il-7、及ccl19之免疫活性細胞 | |
| JP2024023232A5 (fr) | ||
| CN111378625A (zh) | 一种cxcl13趋化型car－t细胞的制备和应用 | |
| CN110267666A (zh) | 用于调节免疫系统的组合物和方法 | |
| AU2018349093A1 (en) | T cell-antigen coupler with Y182T mutation and methods and uses thereof | |
| CN115698081A (zh) | 靶向bcma的嵌合抗原受体及其用途 | |
| WO2022029431A1 (fr) | Récepteur chimérique liant le tgf-bêta | |
| CN111875712A (zh) | 一种增强型靶向muc1的嵌合抗原受体及其应用 | |
| CN110845621A (zh) | 一种靶向egfr和cd19双靶点的嵌合抗原受体方法 | |
| JPWO2019236577A5 (fr) | ||
| JP4635255B2 (ja) | 抗体医薬 | |
| CN115315439A (zh) | 细胞 | |
| CN107446937B (zh) | 嵌合抗原受体及其表达基因、光控调节的嵌合抗原受体修饰的t细胞及其应用 | |
| JP2022537066A (ja) | キメラタンパク質を発現するｔ細胞 | |
| WO2021101467A1 (fr) | Procédé de reconception et d'expansion de cellules nk92 destinées à être utilisées en immunothérapie | |
| JPWO2020163634A5 (fr) |